1-8 of 8
terminal patient care
Close
Sort by
Journal Articles

Cost-Effectiveness Analysis of Gilteritinib Versus Salvage Chemotherapy (SC) for the Treatment of Relapsed or Refractory (R/R) FLT3 -Mutated ( FLT3 mut+ ) Acute Myeloid Leukemia (AML)

Amer M. Zeidan, MBBS, MHS, Cynthia Z. Qi, MBA, Bhavik J. Pandya, PharmD, Andy Garnham, Hongbo Yang, Manasee V Shah, MPH
Journal: Blood
Blood (2019) 134 (Supplement_1): 3859.
https://doi.org/10.1182/blood-2019-123819
Published: 2019
Journal Articles

Cost-Effectiveness Analysis of Gilteritinib Versus Best Supportive Care (BSC) for the Treatment of Relapsed or Refractory (R/R) FLT3 Mutation-Positive ( FLT3 mut+ ) Acute Myeloid Leukemia (AML)

Amer M. Zeidan, MBBS, MHS, Bhavik J. Pandya, PharmD, Cynthia Z. Qi, MBA, Andy Garnham, Hongbo Yang, Manasee V Shah, MPH
Journal: Blood
Blood (2019) 134 (Supplement_1): 5085.
https://doi.org/10.1182/blood-2019-123811
Published: 2019
Journal Articles

Improving End of Life Care for Hematology-Oncology Patients within the Rossy Cancer Network

Victoria Korsos, BSc, Allaa Ali, MPH, Doneal Thomas, M.Phil, M.Sc, Kelly L. Davison, MD PhD, Sarit Assouline, MD, Luca Petruccelli, Chantal Cassis, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4775.
https://doi.org/10.1182/blood-2019-129428
Published: 2019
Journal Articles

Cost-Effectiveness of Midostaurin in the Treatment of Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in the United States

Eytan M. Stein, MD, Jipan Xie, MD PhD, Emilie Duchesneau, Subrata Bhattacharyya, PhD, Briana Ndife, MPH, Gaetano Bonifacio, MD, George J Joseph, BPharm, MS, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4703.
https://doi.org/10.1182/blood.V130.Suppl_1.4703.4703
Published: 2017
Journal Articles

Health Care Utilization and End of Life Care for Older Patients with Acute Myeloid Leukemia Receiving Supportive Care Alone

Areej El-Jawahri, MD, Sean F. Heavey, BS, Thomas W. LeBlanc, MD MA, Harry Vandusen, BS, Gregory Abel, MD MPH, David P. Steensma, MD, Lara Traeger, PhD, Amir T. Fathi, MD, Daniel J. DeAngelo, MD PhD, Martha Wadleigh, MD, Gabriela Hobbs, MD, Philip C. Amrein, MD, Richard M. Stone, MD, Karen K. Ballen, MD, Yi-Bin Chen, MD, Jennifer S. Temel, MD
Journal: Blood
Blood (2015) 126 (23): 2126.
https://doi.org/10.1182/blood.V126.23.2126.2126
Published: 2015
Journal Articles

Pomalidomide Plus Low-Dose Dexamethasone (POM + LoDEX) for Relapsed and Refractory Multiple Myeloma (RRMM): Results from a Pharmacoeconomic Evaluation

Steve Schey, Sujith Dhanasiri, Dawn Lee, Lars Sternas, MD, Xin Yu, Mohamed H. Zaki, MD, Jamie Elvidge, Michael O'Dwyer
Journal: Blood
Blood (2014) 124 (21): 2649.
https://doi.org/10.1182/blood.V124.21.2649.2649
Published: 2014
Journal Articles

Serum Free Light Chain Assays in the Early Detection of Cast Nephropathy in Patients Presenting with Unexplained Acute Kidney Injury (AKI): Results from a Pharmacoeconomic Evaluation

Mark Cook, PhD FRCPath, Paul Cockwell, Christine Almond, Holly Cranmer, Stephen Harding, MDPhD, Richard Hughes, Chris Knight, Alexander Hirst
Journal: Blood
Blood (2014) 124 (21): 2612.
https://doi.org/10.1182/blood.V124.21.2612.2612
Published: 2014
Journal Articles

Outcomes of Pulmonary Embolism In Surgical Patients: A Retrospective Cohort Study

Gauruv Bose, Esteban Gandara, Marc Carrier, MD, MSc, Petra Erkens, MG, Marc Rodger, Philip Wells, MD, FRCPC, MSc
Journal: Blood
Blood (2010) 116 (21): 3180.
https://doi.org/10.1182/blood.V116.21.3180.3180
Published: 2010